In this online, self-learning activity:
Major depressive disorder (MDD) is presently and has been a persistent major public health burden for several decades.1-5 Based on the National Comorbidity Survey data using the Composite International Diagnostic Interview, the estimated risk of MDD over any given 12-month period is 6.6% (13.1 – 14.2 million U.S. adults), with an estimated lifetime risk of 16.2% (32.6 – 35.1 millions US adults). Another estimate, from a recent wave of the National Health and Nutrition Examination Survey, indicates that 17.53% of men and 25.52% of women across all ages report having experienced depressive symptoms in the past. Unfortunately, 58.8% of adults with symptoms classified as moderate and 36.9% of adults with symptoms classified as severe neither saw mental health professional nor received pharmacological treatment, suggesting a gap between present and optimal treatment of MDD.
Healthcare professionals specializing in: family medicine, internal medicine, mental health, neurology and psychiatry, or those who otherwise commonly care for patients with MDD or related psychiatric diseases.
This program is supported by an educational grant from Valeant.
Release Date: July 18, 2017 -- Expiration Date: July 18, 2019
Faculty: Bruce Spring, MD
- Faculty member introduction, disclosures
- Major findings from APA 2017, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content)
By the end of the session the participant will be able to:
CREDIT FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Bruce Spring, M.D. is a stock holder of Pfizer.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Valeant
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.